TLN vs. VRNA

Last updated Jun 9, 2026

TLN (Talen Energy Corporation) and VRNA (Verona Pharma plc) are both stocks. TLN operates in Utilities - Independent Power Producers (Utilities), while VRNA operates in Biotechnology (Healthcare). At a 0.17 correlation, their price movements are largely independent.

Performance

TLN vs. VRNA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Talen Energy Corporation (TLN) and Verona Pharma plc (VRNA). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

TLN

• 1D: 0.01%
• 1M: -5.59%
• YTD: -2.68%
• 6M: 3.23%
• 1Y: 41.09%
• 3Y*: 99.41%
• 5Y*: —
• 10Y*: —

VRNA

• 1D: —
• 1M: —
• YTD: —
• 6M: —
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

TLN vs. VRNA - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023
TLN Talen Energy Corporation	-2.68%	86.05%	214.80%	38.01%
VRNA Verona Pharma plc	0.00%	130.21%	133.60%	-9.14%

Correlation

The correlation between TLN and VRNA is -0.00, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	-0.00
Correlation (3Y) Calculated over the trailing 3-year period	0.17
Correlation (All Time) Calculated using the full available price history since Jun 2, 2023	0.17

The correlation between TLN and VRNA shifts across timeframes, from -0.00 (1 year) to 0.17 (all time), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap TLN : $17.30B VRNA : $9.72B
EPS TLN : -$0.44 VRNA : -$0.69
PS Ratio TLN : 5.76 VRNA : 57.97
PB Ratio TLN : 16.12 VRNA : 34.92
Total Revenue (TTM) TLN : $3.02B VRNA : $167.65M
Gross Profit (TTM) TLN : $1.06B VRNA : $159.52M
EBITDA (TTM) TLN : $326.00M VRNA : -$40.86M

Return for Risk

TLN vs. VRNA — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

TLN

TLN Risk / Return Rank: 65
TLN Sharpe Ratio Rank: 66
TLN Sortino Ratio Rank: 65
TLN Omega Ratio Rank: 63
TLN Calmar Ratio Rank: 67
TLN Martin Ratio Rank: 65

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

TLN vs. VRNA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Talen Energy Corporation (TLN) and Verona Pharma plc (VRNA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	TLN	VRNA	Difference
Sharpe ratio: Return per unit of total volatility	0.73	—	—
Sortino ratio: Return per unit of downside risk	1.41	—	—
Omega ratio: Gain probability vs. loss probability	1.17	—	—
Calmar ratio: Return relative to maximum drawdown	1.29	—	—
Martin ratio: Return relative to average drawdown	2.62	—	—
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

Sharpe Ratios by Period

	TLN	VRNA	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.73	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	1.98	—	—

Drawdowns

Drawdown Indicators

	TLN	VRNA	Difference
Max Drawdown Largest peak-to-trough decline	-33.80%	—	—
Max Drawdown (1Y) Largest decline over 1 year	-32.05%	—	—
Max Drawdown (3Y) Largest decline over 3 years	-33.80%	—	—
Current Drawdown Current decline from peak	-18.18%	—	—
Average Drawdown Average peak-to-trough decline	-7.27%	—	—
Ulcer Index Depth and duration of drawdowns from previous peaks	15.71%	—	—

Volatility

Volatility by Period

	TLN	VRNA	Difference
Volatility (1M) Calculated over the trailing 1-month period	16.60%	—	—
Volatility (6M) Calculated over the trailing 6-month period	41.46%	—	—
Volatility (1Y) Calculated over the trailing 1-year period	56.37%	—	—
Volatility (5Y) Calculated over the trailing 5-year period, annualized	49.91%	—	—
Volatility (10Y) Calculated over the trailing 10-year period, annualized	49.91%	—	—

Dividends

TLN vs. VRNA - Dividend Comparison

Neither TLN nor VRNA has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials

TLN vs. VRNA - Profitability Comparison

The chart below illustrates the profitability comparison between Talen Energy Corporation and Verona Pharma plc over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

TLN - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Talen Energy Corporation reported a gross profit of 0.00 and revenue of 1.13B. Therefore, the gross margin over that period was 0.0%.

VRNA - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Verona Pharma plc reported a gross profit of 71.68M and revenue of 75.14M. Therefore, the gross margin over that period was 95.4%.

TLN - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Talen Energy Corporation reported an operating income of 210.00M and revenue of 1.13B, resulting in an operating margin of 18.6%.

VRNA - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Verona Pharma plc reported an operating income of 9.69M and revenue of 75.14M, resulting in an operating margin of 12.9%.

TLN - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Talen Energy Corporation reported a net income of 63.00M and revenue of 1.13B, resulting in a net margin of 5.6%.

VRNA - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Verona Pharma plc reported a net income of 8.69M and revenue of 75.14M, resulting in a net margin of 11.6%.

Frequently Asked Questions

Can I hold both TLN and VRNA in my portfolio?

TLN and VRNA have a correlation of -0.00, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.